Quantcast

Stem Cell Research Uncovers Mechanism for Type 2 Diabetes

December 8, 2009
biotech

LA JOLLA, Calif., February 12, 2009—Taking clues from their stem cell research, investigators at the University of California San Diego and Burnham Institute for Medical Research have discovered that a signaling pathway involved in normal pancreatic development is also associated with type 2 diabetes.


Scientists Identify Human Monoclonal Antibodies Effective Against Bird and Seasonal Flu Viruses

December 8, 2009
biotech

February 22, 2009–Researchers at the Dana-Farber Cancer Institute, Burnham Institute for Medical Research and the Centers for Disease Control and Prevention have reported the identification of human monoclonal antibodies (mAb) that neutralize an unprecedented range of influenza A viruses, including avian influenza A (H5N1) virus, previous pandemic influenza viruses, and some seasonal influenza viruses. These antibodies have the potential for use in combination with other treatments to prevent or treat certain types of avian and seasonal flu.


Protein is Key to Embryonic Stem Cell Differentiation

December 8, 2009
biotech

March 18, 2009 — Investigators at Burnham Institute for Medical Research (Burnham) have learned that a protein called Shp2 plays a critical role in the pathways that control decisions for differentiation or self-renewal in both human embryonic stem cells (hESCs) and mouse embryonic stem cells (mESCs).

Gene therapy and stem cells save limb

December 8, 2009
biotech

[NEWS]

Contact: Audrey Huang audrey@jhmi.edu 410-614-5105 Johns Hopkins Medical Institutions Blood vessel blockage, a common condition in old age or diabetes, leads to low blood flow and results in low oxygen, which can kill cells and tissues. Such blockages can require amputation resulting in loss of limbs. Now, using mice as their model, resea…

Hops compound may prevent prostate cancer

December 8, 2009
biotech

[NEWS]

Contact: Tara Yates tara.yates@aacr.org 267-646-0558 American Association for Cancer Research HOUSTON – The natural compound xanthohumol blocks the effects of the male hormone testosterone, therefore aiding in the prevention of prostate cancer. “We hope that one day we can demonstrate that xanthohumol prevents prostate cancer devel…

Researchers finds hidden sensory system in the skin

December 8, 2009
biotech

[NEWS]

Contact: Alex Brownstein alexb@intidyn.com 866-610-7581 ×104 Integrated Tissue Dynamics (INTIDYN) Persons lacking known nerve receptors can still touch and feel; may shed light on causes of unexplained pain such as fibromyalgia December 15, 2009 – (Albany, N.Y., USA) The human sensory experience is far more complex an…


Southwest Fla biotech emerges

December 7, 2009
biotech

60 people who attended a meeting this week of the Southwest Chapter of BioFlorida, an industry association in Florida since …Click Here to Read More


Is Fla. biotech sector the light at the end of the recession?

December 7, 2009
biotech

But Florida made a smart investment in establishing a vibrant biotechnology sector in our state that is now taking root. …Click Here to Read More

Burnham Researcher Awarded $8 Million Grant

December 7, 2009
biotech

LA JOLLA, Calif., September 16, 2008 — Burnham Institute for Medical Research today announced that Stuart A. Lipton, M.D., Ph.D., professor and director of the Del E. Webb Neuroscience, Aging, and Stem Cell Research Center at Burnham has been awarded $8 million, over five years, to establish a Center for Neurodegeneration Science (CNS). The center will study potential environmental causes of ParkinsonÂ’s disease. Funding for the center comes from the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health.

Identification of Human Factors May Yield Novel Therapeutic Targets for HIV

December 7, 2009
biotech

LA JOLLA, Calif., Oct. 2, 2008 — The Salk Institute for Biological Studies and Burnham Institute for Medical Research today announced the identification of 295 host cell factors that are involved in human immunodeficiency virus (HIV) infection. The study, published in the Oct. 3 issue of Cell, could lead to the development of a new class of HIV therapeutics aimed at disrupting the human-HIV interactions that lead to viral infection.